Bright Minds Biosciences DRUG 深 沪
已收盘 07-02 16:00:00 美东时间
67.60
+1.060
+1.59%
华盛通- 最 高69.50
- 今 开67.00
- 成交量 23.47万股
- 最 低 65.83
- 昨 收 66.54
- 总市值 6.63亿
- 52周最高 123.75
- 市盈率 静 --
- 换手率 2.39%
- 52周最低 24.00
- 委 比 -60.16%
- 总股本 981.21万
- 历史最高 123.75
- 量 比 0.69
- 振 幅 5.52%
- 历史最低 0.93
- 每 手 1
- 风险率 19.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
Bright Minds grants stock options for 109,000 shares at US$ 83.4 each
Bright Minds grants stock options for 109,000 shares at US$ 83.4 each Bright Minds Biosciences granted stock options to directors, officers, consultants for 109,000 common shares under its share option plan. Options carry an exercise price of US$ 83.4 per share, expire five years from the grant date
05-28 18:06
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220
Piper Sandler analyst Yasmeen Rahimi maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Overweight and raises the price target from $190 to $220.
05-21 01:28
Bright Minds net loss widens to CAD 18.02 million in FY26 first half
Bright Minds net loss widens to CAD 18.02 million in FY26 first half Bright Minds Biosciences reported a net and comprehensive loss of CAD 10.46 million for the three months ended March 31, 2026, widening from CAD 2.95 million a year earlier. Basic and diluted loss per share deepened to CAD 1.09 fro
05-20 18:02
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145
Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $145.
04-13 20:21
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
03-30 17:57
'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment
https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-treatment-for-veterans/
03-28 01:28
